Table 5 Multivariate analysis for Relapse, NRM, LFS, OS, and GRFS

ATG vs PTCy

0.93 (0.63–1.37)

0.71

1.04 (0.65–1.66)

0.86

0.98 (0.74–1.29)

0.86

0.94 (0.7–1.27)

0.71

0.89 (0.7–1.13)

0.35

Age (per 10 years)

1.01 (0.92–1.11)

0.9

1.37 (1.2–1.56)

< 10–5

1.13 (1.05–1.22)

0.001

1.21 (1.12–1.32)

< 10–5

1.06 (1–1.14)

0.07

sec. AML vs de novo

1.14 (0.86–1.53)

0.36

1.39 (1.02–1.9)

0.04

1.24 (1.01–1.53)

0.04

1.29 (1.03–1.6)

0.02

1.25 (1.03–1.52)

0.02

Adverse cytogenetics vs other

1.77 (1.41–2.24)

< 10–5

1.19 (0.88–1.61)

0.27

1.51 (1.26–1.81)

< 10–5

1.42 (1.17–1.72)

0.0004

1.36 (1.15–1.61)

0.0003

Female donor-male recipient vs other

0.54 (0.36–0.8)

0.002

1.46 (1.04–2.05)

0.03

0.89 (0.69–1.15)

0.38

0.93 (0.71–1.22)

0.6

1.11 (0.89–1.38)

0.35

RIC vs MAC

1.06 (0.82–1.36)

0.66

0.84 (0.63–1.13)

0.25

0.97 (0.81–1.17)

0.75

0.91 (0.74–1.11)

0.33

0.98 (0.83–1.15)

0.77

KPS ≥ 90

1.16 (0.9–1.51)

0.26

0.85 (0.64–1.13)

0.27

1.02 (0.84–1.23)

0.86

0.98 (0.81–1.2)

0.87

0.96 (0.81–1.13)

0.60

Patient CMV positivity

0.99 (0.79–1.24)

0.92

1.31 (0.99–1.73)

0.06

1.11 (0.93–1.32)

0.24

1.12 (0.93–1.35)

0.22

1.11 (0.95–1.29)

0.21

Donor CMV positivity

1.17 (0.94–1.45)

0.16

1 (0.77–1.3)

0.98

1.09 (0.92–1.28)

0.33

1.09 (0.91–1.3)

0.34

1.11 (0.96–1.29)

0.16

Year of transplantation

1.04 (0.99–1.1)

0.12

1 (0.94–1.07)

0.99

1.02 (0.98–1.07)

0.26

1.02 (0.98–1.07)

0.37

1.03 (1–1.07)

0.07

PBSC vs BM

0.96 (0.68–1.36)

0.82

1.29 (0.8–2.09)

0.29

1.05 (0.8–1.39)

0.73

1.11 (0.82–1.49)

0.50

1.14 (0.88–1.47)

0.31